Print

AVEG 016

A Phase I, Multicenter, Randomized, Double-blind, Controlled HIV-1 Clinical Trial to Evaluate and Compare the Safety and Immunogenicity of MN rgp120/HIV-1 in Combination with QS21 Adjuvant

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 16, 1993
MN rgp120 Env gp120 B
MN rgp120 Protein
QS21
USA 81
NCT00001044
https://clinicaltrials.gov/show/NCT00001044